Advertisement

Natural History of High-Risk Prostate Cancer

  • Sangjun Yoo
  • In Gab Jeong
Chapter

Abstract

Prostate cancer is the second most common cancer among men worldwidely and more than a million patients were newly diagnosed as prostate cancer [1]. Moreover, in developed countries, prostate cancer is ranked first among male cancer. In the view of mortality, prostate cancer is the fifth most common cause of death among male cancer, and approximately 307,500 patients died from prostate cancer worldwidely in 2012. Given the high incidence of prostate cancer, the number of deaths from prostate cancer is relatively small compared to other cancers. In other words, prostate cancer is relatively indolent cancer, but nevertheless, a huge number of patients die from prostate cancer due to the high incidence of the disease.

References

  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefGoogle Scholar
  2. 2.
    Hall MD, Schultheiss TE, Farino G, Wong JY. Increase in higher risk prostate cancer cases following new screening recommendation by the US Preventive Services Task Force (USPSTF). Am Soc Clin Oncol. 2015;33:143.CrossRefGoogle Scholar
  3. 3.
    Weiner A, Matulewicz R, Eggener S, Schaeffer E. Increasing incidence of metastatic prostate cancer in the United States (2004–2013). Prostate Cancer Prostatic Dis. 2016;19(4):395.CrossRefPubMedGoogle Scholar
  4. 4.
    Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML. Mayo Clinic validation of the D’amico risk group classification for predicting survival following radical prostatectomy. J Urol. 2008;179(4):1354–60. discussion 60-1CrossRefPubMedGoogle Scholar
  5. 5.
    Mohler JL, Armstrong AJ, Bahnson RR, D’Amico AV, Davis BJ, Eastham JA, et al. Prostate cancer, version 1.2016. J Natl Compr Cancer Netw. 2016;14(1):19–30.CrossRefGoogle Scholar
  6. 6.
    Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244–52.PubMedGoogle Scholar
  7. 7.
    Ankerst DP, Hoefler J, Bock S, Goodman PJ, Vickers A, Hernandez J, et al. Prostate cancer prevention trial risk calculator 2.0 for the prediction of low- versus high-grade prostate cancer. Urology. 2014;83(6):1362–8.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Preston MA, Wilson KM, Markt SC, Ge R, Morash C, Stampfer MJ, et al. 5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer. JAMA Intern Med. 2014;174(8):1301–7.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Popiolek M, Rider JR, Andrén O, Andersson S-O, Holmberg L, Adami H-O, et al. Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Eur Urol. 2013;63(3):428–35.CrossRefPubMedGoogle Scholar
  10. 10.
    Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293(17):2095–101.CrossRefPubMedGoogle Scholar
  11. 11.
    van den Ouden D, Schroder FH. Management of locally advanced prostate cancer. 1. Staging, natural history, and results of radical surgery. World J Urol. 2000;18(3):194–203.CrossRefPubMedGoogle Scholar
  12. 12.
    James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. Survival with newly diagnosed metastatic prostate cancer in the “Docetaxel Era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol. 2015;67(6):1028–38.CrossRefPubMedGoogle Scholar
  13. 13.
    Yossepowitch O, Bianco FJ Jr, Eggener SE, Eastham JA, Scher HI, Scardino PT. The natural history of noncastrate metastatic prostate cancer after radical prostatectomy. Eur Urol. 2007;51(4):940–7. discussion 7-8CrossRefPubMedGoogle Scholar
  14. 14.
    Pezaro CJ, Omlin A, Lorente D, Nava Rodrigues D, Ferraldeschi R, Bianchini D, et al. Visceral disease in castration-resistant prostate cancer. Eur Urol. 2014;65(2):270–3.CrossRefPubMedGoogle Scholar
  15. 15.
    Pond GR, Sonpavde G, de Wit R, Eisenberger MA, Tannock IF, Armstrong AJ. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur Urol. 2014;65(1):3–6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Department of UrologySMG-SNU Boramae Medical CenterSeoulSouth Korea
  2. 2.Department of UrologyAsan Medical CenterSeoulSouth Korea

Personalised recommendations